Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) announced on November 12, 2025 that it granted inducement equity awards in connection with the hire of Michael Nofi as Chief Financial Officer, effective the same day. On November 10, 2025 the company granted a stock option to purchase 262,500 shares and an inducement restricted stock unit award covering 43,750 shares under the 2024 Inducement Equity Incentive Plan.

The option’s exercise price is $18.17 per share (equal to the grant‑date closing price). Vesting: options—25% after one year then 1/48th monthly; RSUs—1/4 each year for four years. Awards were granted as inducements per Nasdaq Listing Rule 5635(c)(4).

Positive

• CFO hire granted 262,500 stock options
• Inducement RSUs covering 43,750 shares
• Option exercise price $18.17 equals grant‑date closing price

Negative

• Total potential share awards equal 306,250 shares
• Awards vest over four years, delaying shareholder benefit

BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on November 10, 2025, Edgewise granted an inducement stock option to purchase a total of 262,500 shares of Edgewise's common stock and an award of inducement restricted stock units ("RSU award") covering a total of 43,750 shares of Edgewise's common stock to Michael Nofi, in connection with the commencement of his employment as Chief Financial Officer of the Company, effective today, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). 

The inducement stock option has an exercise price of $18.17 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the grant date, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the his continued service.

The inducement RSU award shall vest as follows: one-fourth (1/4th) of the shares subject to such inducement RSU award shall vest on the first, second, third and fourth yearly anniversaries of the grant date, subject to his continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to Mr. Nofi to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302612016.html

SOURCE Edgewise Therapeutics

FAQ

What inducement awards did Edgewise (EWTX) grant to its new CFO on November 10, 2025?

Edgewise granted a stock option for 262,500 shares and RSUs covering 43,750 shares to Michael Nofi.

What is the exercise price of the Edgewise (EWTX) CFO option and how was it set?

The option exercise price is $18.17 per share, equal to the closing price on the grant date.

How do the Edgewise (EWTX) option vesting terms work for the CFO grant?

Options vest 25% after one year, then an additional 1/48th monthly thereafter, subject to continued service.

What is the vesting schedule for the Edgewise (EWTX) inducement RSUs for the CFO?

The RSUs vest 1/4 on each of the first, second, third and fourth anniversaries of the grant date.

Under what plan were the Edgewise (EWTX) inducement awards granted and why?

Awards were granted under the 2024 Inducement Equity Incentive Plan as inducements material to the CFO hire under Nasdaq Rule 5635(c)(4).